Please assess the completion status of the following clinical trial:

Trial Title: Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males and non-pregnant, non-lactating females age ≥ 18 years.~* Provide written, informed consent.~* Prior completion of an avoralstat therapeutic study OR a confirmed diagnosis of HAE Type 1 or HAE Type 2.~* Access to appropriate medication for the treatment of acute HAE attacks.~* Adequate contraception.~Exclusion Criteria:~* Females who are pregnant or breast feeding.~* Clinically significant medical condition or medical history.~* Abnormal screening ECG, laboratory or urinalysis finding that is clinically significant.~* Investigational drug exposure within 30 days (except avoralstat).~* History of or current alcohol or drug abuse.~* HIV or active HBV or HCV infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- avoralstat (Type: EXPERIMENTAL): Five avoralstat capsules (100 mg) to be taken three times daily by mouth

Based on this trial design, predict the completion outcome and termination type (if applicable).